Background
ACOG supports immediate postpartum long-acting reversible contraception (LARC) insertion (i.e., before hospital discharge after delivery) as a best practice, recognizing its role in preventing rapid repeat and unintended pregnancy.\(^1\) Optimally, patients should be counseled prenatally about the option of immediate postpartum LARC, along with the full range of contraceptive options available. Counseling should include advantages, disadvantages, risks of intrauterine (IUD) expulsion, provider reliance for insertion and removal, contraindications, and alternatives for LARC to allow for informed decision making.\(^2\)

The immediate postpartum period can be a particularly favorable time for intrauterine device (IUD) or contraceptive implant insertion for patients who desire a LARC method. The hospital setting offers convenience for the patient and clinician.\(^1\) People who have recently given birth are often highly motivated to use contraception and are known not to be pregnant.

Research on Expulsion
Expulsion rates for immediate postpartum IUD insertion are higher than for interval or post-abortion insertion, vary by study, and may be as high as 10-27%. Differences in expulsion rates are similar across insertion methods but may differ depending on the experience of the inserter.\(^1\)

The benefits of immediate insertion may outweigh the higher risk of expulsion. Disadvantages of waiting up to six weeks postpartum for interval insertion include failure to return for follow-up and inability to obtain an IUD at the follow-up visit.\(^1\) Evidence from clinical trials and from cost-benefit analyses strongly suggest the effectiveness of immediate postpartum placement in reduction of unintended pregnancy, particularly for those at greatest risk of not receiving postpartum care.\(^2\)

In a study of IUD continuation at six months postpartum among 112 women randomized to immediate IUD insertion at cesarean delivery versus delayed insertion, significantly more women in the immediate postpartum placement group continued the IUD (83% versus 64%).\(^3\) In the delayed group, 39% did not obtain the IUD; 25% did not return for the postpartum visit, and 14% either declined the IUD or had an unsuccessful insertion.

Find additional research on immediate postpartum IUD expulsion in the ACOG LARC Program’s Immediate Postpartum LARC Bibliography Resource Digest.\(^4\)

Immediate Postpartum LARC Placement: A Unique Opportunity for Contraceptive Access
Immediate postpartum LARC presents a unique opportunity for patients to access postpartum contraception, since approximately 10–40% of women do not or are unable to attend the six-week postpartum visit, and 40–75% of women who plan to use an IUD postpartum do not obtain it. Additionally, many women will still have insurance coverage while admitted to the hospital for delivery, and the patient and clinician are in the same place at the same time. This eliminates potential access barriers, including the need for an additional visit and potential loss of insurance coverage after delivery.\(^2\)

Most state Medicaid agencies have published guidance on reimbursement for LARC services at the time of delivery.\(^5\) As demonstrated in several cost-benefit analyses, immediate postpartum LARC is highly cost-effective.\(^6,7\)
ACOG & CDC Recommendations for Immediate Postpartum IUD Placement

Placing an IUD at the time of delivery has few contraindications and is supported by ACOG and the Centers for Disease Control and Prevention (CDC) recommendations. The CDC’s 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (MEC) has been endorsed by ACOG and provides guidance about the safety of postpartum IUD use (see table below). Different scenarios for immediate postpartum initiation of IUDs are classified as Category 1 (no restriction for use) or Category 2 (advantages generally outweigh theoretical or proven risks). Immediate postpartum IUD insertion is contraindicated for women in whom uterine infection (i.e., peripartum chorioamnionitis, endometritis, or puerperal sepsis) or ongoing postpartum hemorrhage are diagnosed (US MEC Category 4).

<table>
<thead>
<tr>
<th>Time from delivery of placenta</th>
<th>LNG IUD</th>
<th>Copper IUD</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10 minutes: breastfeeding</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>&lt;10 minutes: not breastfeeding</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>&gt;10 minutes to &lt;4 weeks</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>&gt;4 weeks</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

1 = no restriction for use  
2 = advantages generally outweigh theoretical or proven risks  
More information about method classifications can be found in the CDC’s 2016 U.S MEC for Contraceptive Use

U.S. Medical Eligibility Criteria for Postpartum IUD Initiation

Additional Resources

- ACOG LARC Program: Immediate Postpartum LARC Medicaid Reimbursement Webpage
- Postpartum Contraceptive Access Initiative (PCAI) Website
- ACOG LARC Program Immediate Postpartum LARC Bibliography Resource Digest
- ACOG LARC Program Immediate Postpartum LARC Implementation Resource Digest

This resource was last updated on July 21, 2020. Please visit the LARC Program website at https://www.acog.org/programs/long-acting-reversible-contraception-larc for more information. Please email larcprogram@acog.org with suggestions or comments.

This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on www.acog.org or by calling the ACOG Resource Center.

While ACOG makes every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

© 2018 by the American College of Obstetricians and Gynecologists, 409 12th Street SW, PO Box 96920, Washington, DC 20090-6920. Individuals and groups providing patient care or clinical education in family planning have permission to copy all or any portion of this resource for noncommercial, educational purposes, provided that no modifications are made and proper attribution is given.